USA • Nasdaq • NASDAQ:REXN
ChartMill assigns a fundamental rating of 2 / 10 to REXN.
ChartMill assigns a valuation rating of 2 / 10 to Rexahn Pharmaceuticals (REXN). This can be considered as Overvalued.
Rexahn Pharmaceuticals (REXN) has a profitability rating of 1 / 10.